Back to top
more

Acorda Therapeutics, Inc. (ACOR)

(Delayed Data from NSDQ)

$0.82 USD

0.82
22,556,834

+0.17 (26.70%)

Updated Dec 2, 2020 04:00 PM ET

After-Market: $0.76 -0.06 (-7.20%) 5:10 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.41%
2Buy17.88%
3Hold9.48%
4Sell5.03%
5Strong Sell1.87%
S&P50010.70%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum D VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 19% (207 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

Acorda Therapeutics, Inc. is a biotechnology company developing and commercializing neurology therapies for Parkinson's disease, migraine and multiple sclerosis. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson's disease and multiple sclerosis. Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

General Information

Acorda Therapeutics, Inc.

420 SAW MILL RIVER ROAD

ARDSLEY, NY 10502

Phone: 914-347-4300

Fax: 914-347-4560

Web: http://www.acorda.com

Email: NA

Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End December
Last Reported Quarter 9/30/2020
Next EPS Date 2/11/2021

EPS Information

Current Quarter EPS Consensus Estimate -0.54
Current Year EPS Consensus Estimate -1.72
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date 2/11/2021

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 0.65
52 Week High 2.78
52 Week Low 0.42
Beta 0.69
20 Day Moving Average 2,470,375.75
Target Price Consensus 3.00

ACOR

% Price Change
4 Week -40.15
12 Week 35.68
YTD -68.31
% Price Change Relative to S&P 500
4 Week -44.94
12 Week 23.44
YTD -72.05
Share Information
Shares Outstanding (millions) 47.96
Market Capitalization (millions) 31.00
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year 109.62%
vs. Previous Quarter 113.51%
   
Sales Growth
vs. Previous Year 11.25%
vs. Previous Quarter 57.93%
   
Price Ratios
Price/Book 0.10
Price/Cash Flow 0.13
Price / Sales 0.19
ROE
9/30/20 -8.60
6/30/20 -19.55
3/31/20 -19.83
ROA
9/30/20 -3.51
6/30/20 -7.36
3/31/20 -7.88
Current Ratio
9/30/20 1.09
6/30/20 1.14
3/31/20 2.38
Quick Ratio
9/30/20 0.88
6/30/20 0.90
3/31/20 2.02
Operating Margin
9/30/20 -15.90
6/30/20 -36.36
3/31/20 -40.57
Net Margin
9/30/20 29.71
6/30/20 -138.66
3/31/20 -131.45
Pre-Tax Margin
9/30/20 26.23
6/30/20 -143.17
3/31/20 -135.74
Book Value
9/30/20 6.54
6/30/20 6.06
3/31/20 6.39
Inventory Turnover
9/30/20 1.10
6/30/20 0.98
3/31/20 1.13
Debt-to-Equity
9/30/20 0.52
6/30/20 0.54
3/31/20 0.72
Debt to Capital
9/30/20 34.01
6/30/20 35.09
3/31/20 41.78